Healio20h
Extended treatment with Skyrizi ‘may ultimately benefit’ refractory Crohn’s disease
Patients with moderate to severe Crohn’s disease who did not achieve clinical response to IV induction with Skyrizi ...
Goodwood44m
It’s up to Caterham to lead the lightweight EV sportscars
With the promise of the Seven's core values in a new package, is Caterham's lightweight Project V the best hope for keen ...
The Manila Times14h
Climb Bio Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Business Updates
Acquired In-Process Research and Development expense: Acquired in-process research and development expense was $51.7 million ...